Indo National acquires 0.79% stake in Medcuore for ₹49.9 lakh
- Indo National Limited acquired an additional 0.79% stake in Medcuore Medical Solutions Private Ltd for ₹49,89,880.
- The total shareholding in MMSPL now stands at 63.07%, with shares purchased at ₹14,056 each.
- Medcuore reported a turnover of ₹1.45 crore in FY26, a significant increase from ₹35.41 lakh in FY25.
- The acquisition is aimed at business expansion and profit generation, with no related party interests involved.

*this image is generated using AI for illustrative purposes only.
Indo National Limited has invested ₹49,89,880 to acquire an additional 0.79% equity stake in Medcuore Medical Solutions Private Ltd (MMSPL). This transaction raises the company's aggregate shareholding in the medical device manufacturer to 63.07%.
The investment was made by way of subscription to equity shares at a price of ₹14,056 per share for 355 shares. The valuation was based on a report issued by a registered valuer dated August 21, 2026. The acquisition does not constitute a related party transaction, and no promoter group entities hold any interest in MMSPL.
Strategic Rationale and Target Profile
MMSPL is engaged in the manufacturing, distribution, and service provision of air monitoring systems and air purifiers. Indo National stated that the objective of this additional investment is to facilitate business growth, generate revenue, and earn profits through the expansion of operations. The target entity operates exclusively within India.
The company indicated that the indicative time period for the completion of the acquisition extends up to FY28. No governmental or regulatory approvals are required for this specific transaction.
Financial Performance of Medcuore
Medcuore Medical Solutions Private Ltd was incorporated on June 7, 2020. The filing discloses the turnover figures for the last three fiscal years, highlighting significant volatility in revenue generation.
| Fiscal Year | Turnover |
|---|---|
| FY26 | ₹1,45,60,000 |
| FY25 | ₹35,41,484 |
| FY24 | ₹47,68,000 |
What the Numbers Show
The disclosed turnover data reveals a sharp divergence in performance between FY25 and FY26. Revenue surged from ₹35.41 lakh in FY25 to ₹1.45 crore in FY26, marking a substantial year-on-year expansion. However, this recent growth contrasts with the FY24 figure of ₹47.68 lakh, indicating that the FY25 dip was likely a temporary contraction rather than a long-term downward trend. The current valuation implies confidence in the sustained upward trajectory observed in the most recent fiscal year.
Historical Stock Returns for Indo National
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.37% | -1.79% | -2.83% | +11.59% | -29.12% | -34.30% |
How will Indo National integrate Medcuore's air purification product lines with its existing plumbing and building materials distribution network to drive cross-selling opportunities?
What specific capital expenditure plans are in place to scale Medcuore's manufacturing capacity to sustain the triple-digit revenue growth observed in FY26?
Given the volatile historical turnover, what key performance indicators or milestones must Medcuore meet by FY28 to justify the current valuation multiple?


































